The Transition From Ambrisentan to Macitentan in Patients With Pulmonary Arterial Hypertension: A Real-word Prospective Study

Background: In a long-term event-driven trial, macitentan has demonstrated beneficial time to clinical worsening in patients with pulmonary arterial hypertension (PAH) and reduced PAH-related hospitalization rates compared with placebo. Macitentan is the most recently approved endothelin receptor an...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Yusi, Luo, Jun, Chen, Jingyuan, Kotlyar, Eugene, Li, Zilu, Chen, Wenjie, Li, Jiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8790043/
https://www.ncbi.nlm.nih.gov/pubmed/35095523
http://dx.doi.org/10.3389/fphar.2021.811700

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8790043/
https://www.ncbi.nlm.nih.gov/pubmed/35095523
http://dx.doi.org/10.3389/fphar.2021.811700

Ejemplares similares